PLoS ONE (Jan 2014)

Assessment of PALB2 as a candidate melanoma susceptibility gene.

  • Lauren G Aoude,
  • Mai Xu,
  • Zhen Zhen Zhao,
  • Michael Kovacs,
  • Jane M Palmer,
  • Peter Johansson,
  • Judith Symmons,
  • Jeffrey M Trent,
  • Nicholas G Martin,
  • Grant W Montgomery,
  • Kevin M Brown,
  • Nicholas K Hayward

DOI
https://doi.org/10.1371/journal.pone.0100683
Journal volume & issue
Vol. 9, no. 6
p. e100683

Abstract

Read online

Partner and localizer of BRCA2 (PALB2) interacts with BRCA2 to enable double strand break repair through homologous recombination. Similar to BRCA2, germline mutations in PALB2 have been shown to predispose to Fanconi anaemia as well as pancreatic and breast cancer. The PALB2/BRCA2 protein interaction, as well as the increased melanoma risk observed in families harbouring BRCA2 mutations, makes PALB2 a candidate for melanoma susceptibility. In order to assess PALB2 as a melanoma predisposition gene, we sequenced the entire protein-coding sequence of PALB2 in probands from 182 melanoma families lacking pathogenic mutations in known high penetrance melanoma susceptibility genes: CDKN2A, CDK4, and BAP1. In addition, we interrogated whole-genome and exome data from another 19 kindreds with a strong family history of melanoma for deleterious mutations in PALB2. Here we report a rare known deleterious PALB2 mutation (rs118203998) causing a premature truncation of the protein (p.Y1183X) in an individual who had developed four different cancer types, including melanoma. Three other family members affected with melanoma did not carry the variant. Overall our data do not support a case for PALB2 being associated with melanoma predisposition.